Pfizer, Lilly, more report Q1, FDA names acting CBER director and an ALS awakening

Q1 earnings reports from major pharmaceutical companies and emerging biotechs highlight a period of strategic growth and market recalibration. Pfizer’s conservative guidance despite beating consensus estimates reflects a focus on long-term exclusivity, particularly following the patent settlement for Vyndamax, while Eli Lilly’s 56% revenue growth underscores the massive demand for obesity treatments like Zepbound. Regulatory instability persists at the FDA, marked by high turnover in leadership roles and concerns over transparency regarding agency priorities and research disclosures. Meanwhile, the ALS research landscape shows renewed promise, with QurAlis and Corcept reporting positive mid-stage data for candidates targeting genetic drivers and survival signals. These developments reflect a broader industry push to balance immediate financial performance with long-term clinical innovation and the restoration of public trust in federal health institutions.